The rapid spread of multidrug-resistant strains of common bacteria pathogens pose a significant threat to public health, calling for an accelerated effort to develop novel antibiotics acting on previously unexplored targets. Most notably, many strains of Staphylococcus aureus, a major source of infections in hospitals, are resistant to commonly used antibiotics. Comparative genomics analysis and gene essentiality studies implicated nicotinic acid mononucleotide (NaMN) adenylyltransferase of the NadD family, the key indispensable enzyme in NAD biogenesis of most bacteria (including S. aureus), as a prominent target for the development of novel antimicrobial agents. In previous studies, first, small molecule inhibitors of NadD enzymes from representative gram-positive and gram-negative bacteria were identified, and then their on- target antibacterial activity was confirmed. Some of the identified compounds also showed strong inhibitory activity against S. aureus NadD enzyme. These results provided validation of the NadD target and set the stage for searching for new inhibitors with substantially improved affinity, selectivity, and antibacterial properties. This goal would be addressed in the proposed project by pursuing the following specific aims: (I) screen the MLPCN small molecule compound library and perform hit optimization to identify high-affinity inhibitors of S. aureus NadD enzyme (with IC50 d1 microM);(II) test confirmed hits by secondary assays and in the counter screen against is functional but structurally distinct human enzyme;(III) assess antibacterial properties and kinetic mechanisms of selected nominated probes. The feasibility of the proposed project is supported by the availability of the pure recombinant target enzyme as well as HTS assay methods developed in preliminary studies. Selected best inhibitors will be used in future work as molecular probes to further explore NAD biosynthesis as a target pathway for the development of novel antibiotics.

Public Health Relevance

The growing incidence of deadly hospital infections by antibiotic-resistant strains of Staphylococcus aureus (such as MRSA) calls for an accelerated effort to develop novel antibiotics acting on previously unexplored targets. The proposed project will apply an HTS-based approach to identify high-affinity inhibitors of the previously validated novel NadD target enzyme from S. aureus. These inhibitors will be further used as molecular probes to explore targeting of NAD biosynthesis in bacterial pathogens and as prototypes for the development of novel antibiotics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Small Research Grants (R03)
Project #
1R03MH095597-01A1
Application #
8262600
Study Section
Special Emphasis Panel (ZRG1-BST-F (50))
Program Officer
Yao, Yong
Project Start
2012-01-15
Project End
2013-11-30
Budget Start
2012-01-15
Budget End
2012-11-30
Support Year
1
Fiscal Year
2012
Total Cost
$48,750
Indirect Cost
$23,750
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Sorci, Leonardo; Blaby, Ian K; Rodionova, Irina A et al. (2013) Quinolinate salvage and insights for targeting NAD biosynthesis in group A streptococci. J Bacteriol 195:726-32